Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
The American Journal of Psychiatry
|
April 1, 2005
Child psychopharmacology, effect sizes, and the big bang
Maju Mathews, Babatunde Adetunji, Joanne Mathews, et al.
Journal of Affective Disorders
|
June 30, 2017
Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial
Atul R Mahableshwarkar, Joseph R Calabrese, Thomas A Macek, et al.
Brain : a Journal of Neurology
|
February 2, 2023
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study
Hana Florian, Deli Wang, Steven E Arnold, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
July 3, 2025
A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome
Amee Revana, Rakesh Bhattacharjee, Jennifer L Miller, et al.
Current Opinion in Pharmacology
|
February 26, 2014
New applications of disease genetics and pharmacogenetics to drug development
Allen D Roses, Ann M Saunders, Michael W Lutz, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
November 11, 2017
Characterization of <i>APOE</i> and <i>TOMM40</i> allele frequencies in the Japanese population
Akira Nishimura, Hidenori Nonomura, Shingo Tanaka, et al.
The Lancet. Neurology
|
February 20, 2021
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Günter U Höglinger, Irene Litvan, Nuno Mendonca, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
October 12, 2020
Advancing combination therapy for Alzheimer's disease
Stephen P Salloway, Jeff Sevingy, Kumar Budur, et al.
Journal of Neurodevelopmental Disorders
|
November 19, 2025
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study
Elizabeth Berry-Kravis, Randi Hagerman, Jonathan Cohen, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
August 11, 2018
TOMMORROW neuropsychological battery: German language validation and normative study
Heather R Romero, Andreas U Monsch, Kathleen M Hayden, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
The American Journal of Psychiatry
|
April 1, 2005
Child psychopharmacology, effect sizes, and the big bang
Maju Mathews, Babatunde Adetunji, Joanne Mathews, et al.
Journal of Affective Disorders
|
June 30, 2017
Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial
Atul R Mahableshwarkar, Joseph R Calabrese, Thomas A Macek, et al.
Brain : a Journal of Neurology
|
February 2, 2023
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study
Hana Florian, Deli Wang, Steven E Arnold, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine
|
July 3, 2025
A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome
Amee Revana, Rakesh Bhattacharjee, Jennifer L Miller, et al.
Current Opinion in Pharmacology
|
February 26, 2014
New applications of disease genetics and pharmacogenetics to drug development
Allen D Roses, Ann M Saunders, Michael W Lutz, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
November 11, 2017
Characterization of <i>APOE</i> and <i>TOMM40</i> allele frequencies in the Japanese population
Akira Nishimura, Hidenori Nonomura, Shingo Tanaka, et al.
The Lancet. Neurology
|
February 20, 2021
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Günter U Höglinger, Irene Litvan, Nuno Mendonca, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
October 12, 2020
Advancing combination therapy for Alzheimer's disease
Stephen P Salloway, Jeff Sevingy, Kumar Budur, et al.
Journal of Neurodevelopmental Disorders
|
November 19, 2025
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study
Elizabeth Berry-Kravis, Randi Hagerman, Jonathan Cohen, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
August 11, 2018
TOMMORROW neuropsychological battery: German language validation and normative study
Heather R Romero, Andreas U Monsch, Kathleen M Hayden, et al.
Page
of 4